Hyman Says Ozempic Works, but Is Not a Risk-Free Shortcut
Hyman acknowledges that semaglutide can suppress appetite, improve blood sugar, and produce weight loss, particularly for people with severe obesity. He also warns about cost, weight regain after stopping, muscle loss, gastrointestinal effects, and uncertain longer-term harms. His specific percentage claims about muscle loss and adverse events are not sourced in the transcript and should not be treated as verified clinical guidance.
- The drug was first used for diabetes and acts on the GLP-1 pathway
- Hyman says nausea, vomiting, and reduced appetite can lead some people to stop
- He argues that lifestyle change is still needed to preserve results after treatment
- He recommends clinical body-composition monitoring and resistance training for longer-term users
- He views severe obesity differently from cosmetic use for small amounts of weight loss
- Medication decisions require individual medical assessment, not this interview alone
“the plus side is that it works”
“it's not just a risk-free solution”